Rofenaid in the control of Pasteurella anatipestifer and Escherichia coli infections in ducklings.
In a series of controlled battery trials, Rofenaid (at doses ranging from 0.02 to 0.12% active drug in feed) was administered to ducklings infected experimentally with Pasteurella anatipestifer and Escherichia coli strains. Against P. anatipestifer, Rofenaid at 0.02 to 0.12% levels in feed either prevented or reduced mortality, gross lesions, and bacterial isolations. Furthermore, the weight gain and feed conversion of infected Rofenaid-medicated ducklings were superior to those of uninfected unmedicated controls in two out of three trials. Against E. coli, Rofenaid at 0.02 to 0.08% levels in feed either prevented or reduced mortality, gross lesions, and bacterial isolations. Weight gain and feed conversion of infected Rofenaid-medicated ducklings were also superior to those of uninfected unmedicated controls in two out of three trials. It appears that Rofenaid, at a 0.02-0.08% level, controls infections in ducklings caused by P. anatipestifer and E. coli strains sensitive to this compound.
D000818:Animals; D004359:Drug Therapy, Combination; D004372:Ducks; D004927:Escherichia coli Infections / Q000517:prevention & control / Q000662:veterinary*; D010326:Pasteurella Infections / Q000517:prevention & control / Q000662:veterinary*; D011201:Poultry Diseases / Q000517:prevention & control*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D013412:Sulfadimethoxine / Q000008:administration & dosage* / Q000627:therapeutic use
D011743:Pyrimidines; D013412:Sulfadimethoxine